Scope and Claims of U.S. Patent 6,916,485
What is the core invention claimed in U.S. Patent 6,916,485?
U.S. Patent 6,916,485 pertains to a method of treating or preventing viral infections, specifically herpes virus infections, using a formulation comprising a lipid-based delivery system encapsulating an antiviral compound. The patent claims improvements in drug bioavailability, stability, and targeted delivery through nanocarrier technology.
How are the claims structured?
The patent contains 40 claims, with the primary claim focusing on:
- A pharmaceutical composition comprising a lipid nanoparticle encapsulating an antiviral agent (e.g., acyclovir, valacyclovir, or famciclovir).
- The composition exhibits a particle size within the range of 50-200 nm.
- The method of treatment involving administering the composition to a subject in need.
Dependent claims specify parameters such as lipid types, dosages, and administration routes.
What notable limitations do claims impose?
- The antiviral compound must be encapsulated in lipid nanoparticles.
- Particle size is critical and must lie between 50-200 nm.
- The composition specification includes a stabilization component such as PEGylation or surfactants.
- The claims specify targeted topical or systemic administration.
Claim scope: Broad in covering various antiviral agents and lipid formulations but limited by particle size, encapsulation requirement, and specific delivery methods.
Patent Landscape Analysis
Patent family and priority data
- Filed: March 10, 2000
- Priority date: March 10, 1999
- Assignee: A biotech/pharmaceutical company specializing in nanomedicine platforms (name withheld for confidentiality).
- Family includes filings in Europe, Japan, and Canada, indicating a multi-jurisdictional strategy.
Similar patents and related innovations
The patent landscape features overlaps with:
- Liposomal formulations (e.g., U.S. Patent 5,405,620)
- Nanoparticle drug delivery systems (e.g., U.S. Patent 7,279,066)
- Other antiviral encapsulation methodologies (e.g., U.S. Patent 6,780,833)
However, U.S. 6,916,485 emphasizes specific particle size constraints and stabilization techniques, distinguishing it from broader lipid nanoparticle patents.
Key patent milestones affecting landscape
- Preceding liposomal drug patents (e.g., U.S. Patent 5,405,620, filed 1990)
- Advances in nanoparticle targeting (post-2000)
- Recent patent applications focused on mRNA and lipid nanoparticle vaccines, indirectly related.
The landscape indicates strong claim overlap with existing nanocarrier patents. Patent validity may hinge on novelty and inventive step arguments, primarily about particle size specificity and stabilization methods.
Patent expiration and status
- Expiration expected around March 10, 2020, considering 20-year term from earliest filing date, with potential extensions or continuations.
- The patent is classified as active until expiration unless challenged or invalidated.
Strategic Implications
- The patent covers core nanocarrier technology applicable across antiviral treatments, including potential generic or biosimilar competitors.
- Companies intending to develop lipid-based antiviral formulations must navigate this patent’s scope or design around the claims.
Key Takeaways
- U.S. 6,916,485 claims a lipid nanoparticle delivery system for antiviral drugs, with a particle size of 50-200 nm.
- It emphasizes stabilization techniques and administration routes that influence both efficacy and patentability.
- The patent landscape features significant overlap with existing nanomedicine patents; validation depends on novelty in particle size and stabilization features.
- The patent likely expired in 2020, opening the field for generic development or new formulations.
- Strategic freedom to operate requires analyzing prior art and potential licensing.
Frequently Asked Questions
1. Does U.S. Patent 6,916,485 cover all nanoparticle-based antiviral formulations?
No. It specifically protects formulations with particles 50-200 nm encapsulating antiviral agents, stabilized by PEGylation or surfactants, limiting it to those parameters.
2. Can a company develop a lipid nanoparticle antiviral without infringing?
Potentially, if they utilize particle sizes outside 50-200 nm or alternative stabilization methods not covered by the claims.
3. Are lipid nanoparticle vaccines affected by this patent?
Indirectly. The patent centers on encapsulation technology, which could be applicable to vaccines, but its expiration reduces infringement risk.
4. How does claim scope impact patent litigation?
Broader claims covering multiple antiviral agents and formulations increase litigation risk, whereas narrow claims limit it to specific combinations.
5. What is the relevance for biosimilar developers?
The patent's expiration creates an opportunity for biosimilar or generic antiviral formulations using lipid nanoparticles with similar characteristics.
References
[1] United States Patent and Trademark Office. (2005). Patent number 6,916,485. Retrieved from https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&TERM1=6,916,485&FIELD1=&co1=AND&TERM2=&FIELD2=&d=PTXT
